Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy.
Alladapt Immunotherapeutics has raised $50.0M in total funding. The most recent round was Debt Financing. The last funding was announced in August 2022.
Alladapt Immunotherapeutics's investors include Novartis, Patient Square Capital, Hercules Capital, Red Tree Venture Capital, Anne Wojcicki.
Alladapt Immunotherapeutics is headquartered in Menlo Park, United States.
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy.
Alladapt Immunotherapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alladapt Immunotherapeutics — Funding & Investors." VCBacked, August 30, 2022, https://www.vcbacked.co/company/alladapt-immunotherapeutics. Accessed September 30, 2026.
VCBacked. (2022). Alladapt Immunotherapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/alladapt-immunotherapeutics
{{cite web |title=Alladapt Immunotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alladapt-immunotherapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated